Trial Profile

A Phase 1/2a, Dose-escalation Study of FF-10502-01 for the Treatment of Advanced Solid Tumors and Lymphomas

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 21 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FF 10502 (Primary)
Indications Cholangiocarcinoma; Gallbladder cancer; Lymphoma; Pancreatic cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions; First in man
Sponsors FujiFilm Pharmaceuticals USA

Most Recent Events

23 Apr 2026 Change in evolution of time formal for study primary endpoint with treatment arms.
07 Mar 2023 Results (n=40 of phase 2) assessing the safety, tolerability, and antitumor activity of FF-10502-01 in patients with solid tumors published in the Cancer
01 Jun 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com